{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:37:57Z","timestamp":1791992277239,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Clinical Electrophysiology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jacep.2022.12.021","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T13:58:04Z","timestamp":1677074284000},"page":"1172-1180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"P2","title":["The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6389-0643","authenticated-orcid":false,"given":"Soroosh","family":"Kiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6280-101X","authenticated-orcid":false,"given":"Michael N.","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal M.","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy B.","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"De Lurgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Thompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel R.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhael F.","family":"El-Chami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacep.2022.12.021_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v7.i2.76","article-title":"Flecainide: current status and perspectives in arrhythmia management","volume":"7","author":"Andrikopoulos","year":"2015","journal-title":"World J Cardiol"},{"key":"10.1016\/j.jacep.2022.12.021_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0735-1097(86)80190-5","article-title":"Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide","volume":"8","author":"Morganroth","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2022.12.021_bib3","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","volume":"324","author":"Echt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2022.12.021_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199207233270403","article-title":"Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction","volume":"327","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2022.12.021_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation","volume":"13","author":"Aliot","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.jacep.2022.12.021_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1753944720926824","article-title":"Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12\u00a0months: a retrospective study","volume":"14","author":"Muzzey","year":"2020","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"21","key":"10.1016\/j.jacep.2022.12.021_bib7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2022.12.021_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2018.05.026","article-title":"Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction","volume":"832","author":"Hemmeryckx","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacep.2022.12.021_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000138310","article-title":"Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction","volume":"35","author":"Lynch","year":"1987","journal-title":"Pharmacology"},{"key":"10.1016\/j.jacep.2022.12.021_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction","volume":"321","author":"Investigators","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2022.12.021_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199207233270403","article-title":"Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction","volume":"327","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2022.12.021_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40256-021-00483-9","article-title":"Use of flecainide in stable coronary artery disease: an analysis of its safety in both nonobstructive and obstructive coronary artery disease","volume":"21","author":"Ashraf","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacep.2022.12.021_bib13","article-title":"Abstract 15345: long-term outcomes in patients treated with flecainide for atrial fibrillation with severe coronary artery disease treated with revascularization","volume":"140","author":"Bunch","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2022.12.021_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ahj.2021.08.013","article-title":"Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease","volume":"243","author":"Burnham","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2022.12.021_bib15","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1055\/s-2008-1068315","article-title":"[Elevated plasma flecainide concentrations in heart failure]","volume":"112","author":"Nitsch","year":"1987","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jacep.2022.12.021_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(85)90413-2","article-title":"Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease","volume":"109","author":"Josephson","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2022.12.021_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0735-1097(87)80096-7","article-title":"Influence of left ventricular dysfunction on flecainide therapy","volume":"9","author":"de Paola","year":"1987","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2022.12.021_bib18","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/europace\/eus087","article-title":"Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study","volume":"14","author":"Davis","year":"2012","journal-title":"Europace"}],"container-title":["JACC: Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X23000038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X23000038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:32:03Z","timestamp":1762500723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405500X23000038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2405500X23000038"],"URL":"https:\/\/doi.org\/10.1016\/j.jacep.2022.12.021","relation":{},"ISSN":["2405-500X"],"issn-type":[{"value":"2405-500X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Clinical Electrophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2022.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}